Newsfiscal.ai
Cellectar Biosciences Reports Durable Complete Response in Heavily Pretreated DLBCL Patient
· Published
Article summary
Cellectar Biosciences announced a case study of a patient with relapsed diffuse large B-cell lymphoma who achieved a durable complete response lasting over eight years following a single administration of iopofosine I 131.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…